Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Jun 14, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a condition called post-COVID-19 tachycardia syndrome, which often affects people who have had COVID-19. Many of these patients, especially women, experience symptoms like a fast heartbeat, dizziness when standing up, fatigue, headaches, and trouble concentrating. The researchers believe that ongoing inflammation and reduced nerve activity in the body may play a role in these symptoms, and they want to learn more about how these factors contribute to this condition.

To participate in the trial, individuals must have had a confirmed COVID-19 infection and be experiencing a fast heartbeat and other related symptoms for at least three months. However, certain health conditions, such as heart disease, uncontrolled high blood pressure, or diabetes, may exclude someone from joining. Participants will help researchers understand this syndrome better and may contribute to finding effective treatments. If you or someone you know has been affected by these lingering symptoms after COVID-19, this study could be an important step in addressing their health concerns.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prior RT-PCR-confirmed COVID-19 infection.
• • Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms.
• Exclusion criteria:
• • Heart Disease: Myocardial Infarction, angina, heart failure
• • History of stroke, or transient ischemic attack
• • Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries)
• • Uncontrolled hypertension defined as persistent blood pressure \>140/90.
• • Post-menopausal women.
• • Diabetes Mellitus Type 1 or Type 2. ,
• • Impaired Hepatic function
• • Impaired renal function test (eGFR\<60 mL/min/1.73m2).
• • Ongoing substance abuse.
• • Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study.
• • History of seizures.
• • Chronic use of steroids, NSAIDs.
• • On biologics such as anti-IL6 (omalizumab) and anti-TNF-alpha drugs
• • Pregnancy or breastfeeding